Cerevel Therapeutics develops therapies for neuroscience diseases. Emraclidine is in phase 1b trials for schizophrenia treatment. Darigabat is in Phase 2 proof-of-concept trial for drug-resistant seizures and focal epilepsy, and in phase 1 trial for panic symptoms. Tavapadon is in phase 3 clinical trial for Parkinsons disease treatment. CVL-871 is in Phase 2a clinical trial to treat dementia-related apathy. CVL-354 is being developed to treat major depressive disorder and substance use disorder. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 0.1 |